natalizumab (Tysabri®)

Status: Medicine does not meet criteria for AWMSG assessment
Excluded from appraisal by AWMSG as meets exclusion criterion 6. See AWMSG criteria for appraising a medicine for information.
Medicine details
Medicine name	natalizumab (Tysabri®)
Formulation	300 mg subcutaneous injection
Reference number	4722
Indication	As single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy; or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI
Company	Biogen Idec Ltd
BNF chapter	Malignant disease & immunosuppression
Assessment type	N/A
Status	Medicine does not meet criteria for AWMSG assessment
Date of issue	30/09/2020